Obesity drug dropped as 'too risky'

GPs warn treatment options should not be limited where a benefit is shown.

Dr Haslam: 'benefits lost'
Dr Haslam: 'benefits lost'

GPs have expressed disappointment at the suspension of the weight-loss drug rimonabant.

Dr Ian Campbell, a GP in Nottingham and medical director of the charity Weight Concern, said prescribers are aware of the drug's adverse effects on anxiety and depression and monitored patients closely.

'It is disappointing for those patients for whom the drug is working,' he said.

Around 20,000 patients in the UK have been treated with rimonabant, marketed as Acomplia, but last week the European Medicines Agency (EMEA) decided that its benefits no longer outweigh its risks.

Prescribers should not issue any new prescriptions for the drug, the EMEA said.

Patients do not need to stop treatment immediately, but those who wish to stop can do so at any time, the EMEA advised.

Dr David Haslam, a GP in Hertfordshire and clinical director of the National Obesity Forum, said the move was 'a great shame'.

'I have patients whose diabetes is well controlled who have benefited from rimonabant and that benefit will end when their treatment ends.'

The drug's manufacturer Sanofi-Aventis said it was complying with the EMEA's recommendation and would provide additional evidence for re-evaluation of the drug's benefit-risk profile in patients with diabetes and cardiovascular disease.

The EMEA said its assessment showed an increased risk of psychiatric disorders in patients taking rimonabant. In addition, the agency said that the drug's effectiveness in clinical practice had been found to be more limited than was expected.

Sir Michael Rawlins, chairman of NICE, told GP that the institute had withdrawn its June guidance, which recommended the drug for third-line use after orlistat and sibutramine.

tom.moberly@haymarket.com.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

More than half of GP locums have seen a significant drop in income due to COVID-19

More than half of GP locums have seen a significant drop in income due to COVID-19

More than half of GP locums have experienced a significant fall in their income during...

How a GP helped develop a protective shield to cover patients needing CPR in the pandemic

How a GP helped develop a protective shield to cover patients needing CPR in the pandemic

Wiltshire GP Dr Lydia Campbell-Hill explains how she helped create a mini isolation...

GP practices can now sign up to new online PPE portal

GP practices can now sign up to new online PPE portal

GP practices will be able to register with the DHSC's new online PPE portal, which...

Fully-qualified GP workforce fell by 712 over the past year

Fully-qualified GP workforce fell by 712 over the past year

The fully-qualified GP workforce in England fell by 2.5%, losing 712 full-time equivalent...

MPs call for expert guidance on medico-legal implications of pandemic

MPs call for expert guidance on medico-legal implications of pandemic

A group of MPs has called on the government to set up an independent expert committee...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...